Specialty Pharmaceuticals
Total Trials
4
As Lead Sponsor
2
As Collaborator
Total Enrollment
213
NCT06746883
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
Phase: N/A
Role: Lead Sponsor
Start: Apr 28, 2025
Completion: Jan 31, 2029
NCT06794541
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Phase: Phase 2
Role: Collaborator
Start: May 22, 2025
Completion: Mar 19, 2029
NCT07212686
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
Phase: Phase 4
Start: Sep 9, 2025
Completion: Jun 30, 2030
NCT06801223
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
Phase: Phase 1
Start: Oct 30, 2025
Completion: May 20, 2028
Loading map...